Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Zekri, Abdel-Rahman N; Bahnassy, Abeer A; Mohamed, Waleed S; Alam EL-Din, Hanaa M; Shousha, Hend I; Zayed, Naglaa; Eldahshan, Dina H; Abdel-Aziz, Ashraf Omar

doi:10.1186/1743-422X-10-218

Virology Journal

Table 4 Different chemokine’s levels of 55 patients at 12 weeks in response to treatment

From: Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Parameter		Pegylated interferon α 2b (PEG-INTRON) (n=31)		Pegylated interferon α 2a (PEGASYS) (n=24)		P-value
		Non-responders (n=10)	Responders (n=21)	Non-responders (n=13)	Responders (n=11)
CXCL5(pg/ml)	Pretreatment	1.45250 ± 940684	1.30990 ± .759433	1.44500 ± 1.077797	1.43018 ± .878441	0.000^a, 0.486^b, 0.593^c, 0.236^d, 0.665^e, 0.552^f
CXCL5(pg/ml)	12 Weeks	.71740 ± .377958	.88486 ± .588673	1.25877 ± 851592	.80655 ± .578292	0.000^a, 0.486^b, 0.593^c, 0.236^d, 0.665^e, 0.552^f
CXCL9(pg/ml)	Pretreatment	.20700 ± .102838	.19700 ± .078764	.19854 ± .134327	.18836 ± .059980	0.492^a, 0.555^b, 0.256^c, 0.239^d, 0.174^e, 0.393^f
CXCL9(pg/ml)	12 Weeks	.15520 ± .105935	.14029 ± .039694	.28985 ± .489042	.12573 ± .053301	0.492^a, 0.555^b, 0.256^c, 0.239^d, 0.174^e, 0.393^f
CXCL11(pg/ml)	Pretreatment	.13520 ± .080444	.13905 ± .074375	.17885 ± .093798	.16373 ± .103128	0.144^a, 0.190^b, 0.787^c, 0.435^d, 0.065^e, 0.634^f
CXCL11(pg/ml)	12 Weeks	.15260 ± .081185	.16190 ± .098519	.17154 ± .049891	.19991 ± .152004	0.144^a, 0.190^b, 0.787^c, 0.435^d, 0.065^e, 0.634^f
CXCL12(pg/ml)	Pretreatment	51.01730 ± 206.396544	.39581 ± .154332	.58746 ± .244147	.43218 ± .163781	0.187^a, 0.185^b, 0.182^c, 0.229^d, 0.065^e, 0.188^f
CXCL12(pg/ml)	12 Weeks	.50380 ± . 065023	.42181 ± .147961	.61662 ± . 196068	.42227 ± . 205439	0.187^a, 0.185^b, 0.182^c, 0.229^d, 0.065^e, 0.188^f
CXCL13(pg/ml)	Pretreatment	.35510 ± .069974	.31505 ± .105584	.45677 ± .274538	.29830 ± . 105315	0.001^a, 0.753^b, 0.017^c, 0.329^d, 0.251^e, 0.072^f
CXCL13(pg/ml)	12 Weeks	.49510 ± .139194	.42638 ± .246432	.56569 ± . 271026	.33490 ± .145816	0.001^a, 0.753^b, 0.017^c, 0.329^d, 0.251^e, 0.072^f
CXCL16(ng/ml)	Pretreatment	1.00250 ± .101567	.87652 ± . 244527	1.16792 ± . 424545	1.01791 ± .331579	0.000^a, 0.081^b, 0.227^c, 0.689^d, 0.378^e, 0.702^f
CXCL16(ng/ml)	12 Weeks	1.12440 ± .298719	1.11633 ± . 323698	1.36885 ± . 342009	1.23936 ± .417217	0.000^a, 0.081^b, 0.227^c, 0.689^d, 0.378^e, 0.702^f
E-cadherin(ng/ml)	Pretreatment	.82420 ± .425530	.47852 ± .436687	.98600 ± .843119	.63418 ± .660015	0.240^a, 0.426^b, 0.041^c, 0.864^d, 0.748^e, 0.794^f
	12 Weeks	.95180 ± .666040	.55862 ± .577851	1.09185 ± .782186	.68536 ± . 657444

p-value comparing the effect of time^a, treatment type^b, response to treatment^c, time-type interaction^d, time-response interaction^e, type-response interaction^f.

Back to article page

ISSN: 1743-422X

Contact us

Submission enquiries: journalsubmissions@springernature.com